The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
June 11th 2024
Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Durvalumab Associated With Lower Real-World PFS in EGFR-Mutated NSCLC Vs EGFR Wild-Type NSCLC
Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.
Frontline Osimertinib/Chemotherapy Combination Improves PFS in EGFR-Mutated NSCLC
September 11th 2023Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.
Interim Results Show Durable Response With Dato-DXd in Advanced NSCLC
September 11th 2023The addition of datopotamab deruxtecan to durvalumab, with or without carboplatin, demonstrated favorable efficacy and safety in patients with advanced or metastatic non–small cell lung cancer, according to an interim analysis of the phase 1b TROPION-Lung04 trial.
TNO155/JDQ433 Combo Elicits Responses, Is Tolerable in KRAS G12C+ Solid Tumors
The combination of the SHP2 inhibitor TNO155 and the KRAS G12C inhibitor JDQ433 showed antitumor activity in patients with KRAS G12C-mutated solid tumors, including non–small cell lung cancer, irrespective of prior treatment with a KRAS G12C inhibitor.
Dose Optimization Continues After Preliminary Efficacy, Safety Signals With BI 764532 in DLL3+ SCLC
September 10th 2023Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.
Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC
Treatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TKI–naïve, locally advanced and metastatic ALK-positive non–small cell lung cancer, according to data from a prespecified interim analysis of the phase 3 INSPIRE trial.
Furmonertinib Generates Activity and Tolerable Safety in EGFR Exon 20 Insertion+ NSCLC
The use of the oral, brain penetrant, furmonertinib, resulted in encouraging responses and a tolerable safety profile in patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to data from the phase 1b FAVOUR trial.
Repotrectinib Induces Durable Responses in ROS1+ NSCLC Subsets
September 10th 2023Treatment with repotrectinib in patients with ROS1-positive non–small cell lung cancer, specifically those who were tyrosine kinase inhibitor-naïve or -pretreated, continued to demonstrate durable clinical activity, as well as durable intracranial responses.
Patritumab Deruxtecan Elicits Durable Responses in EGFR-Mutated NSCLC
Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.
Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC
September 10th 2023Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.
Frontline Benmelstobart Plus Anlotinib/Chemo Improves Survival Vs Placebo in ES-SCLC
The addition of benmelstobart to anlotinib and etoposide plus carboplatin significantly improved progression-free survival and overall survival over placebo plus etoposide plus carboplatin when used in the first-line treatment of patients with extensive-stage small cell lung cancer.
Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC
September 8th 2023Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.
Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations
September 6th 2023Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.
Amivantamab/Chemotherapy ± Lazertinib Improves PFS in Pretreated EGFR+ NSCLC
September 6th 2023Amivantamab-vmjw plus carboplatin and pemetrexed, administered with or without lazertinib, significantly improved progression-free survival vs chemotherapy alone in patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 19 deletions or L858R substitutions after progression on or after osimertinib.
Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer
September 5th 2023Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.
TKIs, Immunotherapy, and ADCs Amplify the SCLC and NSCLC Treatment Paradigms
September 5th 2023Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.
Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future
September 4th 2023James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in Advanced Nonsquamous NSCLC
September 1st 2023Combination treatment with atezolizumab, carboplatin, and pemetrexed showed activity in patients with advanced nonsquamous non–small cell lung cancer and untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment.
Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC
Adjuvant treatment with alectinib generated a statistically significant and clinically meaningful improvement in disease-free survival compared with platinum-based chemotherapy in patients with completely resected stage IB to IIIA, ALK-positive non–small cell lung cancer.